News Archive

2017

July

Media Release / Jul 25, 2017

Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries

Read More
Media Release / Jul 21, 2017

Novartis receives positive CHMP opinion for Rydapt® (midostaurin) for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)

Read More
Media Release / Jul 18, 2017

Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products

Read More
Media Release / Jul 14, 2017

Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis

Read More
Media Release / Jul 13, 2017

Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL

Read More
Media Release / Jul 06, 2017

Novartis receives approval in the EU for Cosentyx label update, includes long term superiority data versus Stelara in psoriasis

Read More

June

Media Release / Jun 29, 2017

Novartis receives EU approval for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)

Read More
Media Release / Jun 27, 2017

Sandoz receives approval in Europe for Erelzi® (biosimilar etanercept) to treat multiple inflammatory diseases

Read More
Media Release / Jun 23, 2017

NEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)

Read More
Media Release / Jun 23, 2017

Novartis Kisqali® (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor

Read More

Pages

Related Links

Annual Report 2016

Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.

Learn More

Contact Media Relations

For media and journalist inquiries, please contact the Novartis Corporate Media Relations office by email or telephone.

Central Media Line:
Phone: +41 61 324 2200